StockData
Rapport Therapeutics, Inc. logo

Rapport Therapeutics, Inc. (RAPP) stock

RAPPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$23.76−1.06 (-4.27%)

Close on Nov 17, 2026Market cap $1.14BP/E –Yield –

Rapport Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Rapport Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$167.62M. For fiscal 2025 it was -$125.10M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$125.10M–
FY2024Dec 31, 2024-$83.06M–
FY2023Dec 31, 2023-$36.18M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$44.09M–
Q2 FY2026Jun 30, 2026-$60.81M–
Q1 FY2026Mar 31, 2026-$24.22M–
Q4 FY2025Dec 31, 2025-$38.51M–
Q3 FY2025Sep 30, 2025-$29.99M–
Q2 FY2025Jun 30, 2025-$29.50M–
Q1 FY2025Mar 31, 2025-$27.11M–
Q4 FY2024Dec 31, 2024-$23.52M–
Q3 FY2024Sep 30, 2024-$21.64M–
Q2 FY2024Jun 30, 2024-$20.80M–
Q1 FY2024Mar 31, 2024-$17.09M–
Q4 FY2023Dec 31, 2023-$14.79M–
Q3 FY2023Sep 30, 2023-$9.56M–
Q2 FY2023Jun 30, 2023-$6.63M–

More Rapport Therapeutics figures

See a number that looks wrong?